NeoGenomics (NEO) Q1 2025 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Globe and Mail, The
Chief Financial Officer — Jeffrey S. Sherman President and Chief Operating Officer — Warren Stone Chief Innovation Officer — Andrew Lukowiak Head of Strategy and Transformation — Kareem Saad Need a quote from a Motley Fool analyst? Email pr@fool.com TAKEAWAYS Total Revenue -- $168 million, up 8% year over year, with the quarter setting a new record for test volumes and in line with management's 8%-10% Q1 guidance. Adjusted EBITDA -- $7.1 million for Q1, representing over 100% growth compared to the prior year and marking a seventh consecutive quarter of positive adjusted EBITDA. Clinical Testing Volume -- Increased 8% year over year, with next-generation sequencing (NGS) revenue up 18%, and five new NGS products driving 22% of total clinical revenue. Adjusted Gross Margin -- 47%, improved by 146 basis points, resulting in adjusted gross profit of $79 million (up 11% versus prior year). Clinical Revenue -- Rose by $15 million, or 11.3%, while non-clinical revenue d
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics (NEO) had its price target raised by TD Cowen from $13.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- Wall Street's Next Biotech Winners Emerge as FDA Acceleration Unleashes New Markets [TheStreet.com]TheStreet.com
- NeoGenomics (NEO) was upgraded by Leerink Partners from "market perform" to "outperform". They now have a $25.00 price target on the stock.MarketBeat
- NeoGenomics (NEO) was upgraded by Benchmark Co. from "hold" to "buy".MarketBeat
- NeoGenomics (NEO) Q1 2026 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
NEO
Earnings
- 4/28/26 - Beat
NEO
Sec Filings
- 4/29/26 - Form SCHEDULE
- 4/28/26 - Form 10-Q
- 4/28/26 - Form 8-K
- NEO's page on the SEC website